Kevin McCulloch - 31 Jan 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
31 Jan 2025
Net transactions value
-$278,157
Form type
4
Filing time
03 Feb 2025, 19:40:39 UTC
Previous filing
07 Jan 2025
Next filing
03 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $104,308 -29,300 -1.9% $3.56 1,548,152 31 Jan 2025 Direct F1
transaction XERS Common Stock Tax liability $173,849 -48,834 -3.2% $3.56 1,499,318 31 Jan 2025 Direct F1
transaction XERS Common Stock Award $0 +185,000 +12% $0.000000 1,684,318 31 Jan 2025 Direct F2
holding XERS Common Stock 25,000 31 Jan 2025 By Spouse F3
holding XERS Common Stock 2,000 31 Jan 2025 By Charles R. McCulloch Trust dated 1990 F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Appreciation Right Award $0 +500,000 $0.000000 500,000 31 Jan 2025 Common Stock 500,000 $3.56 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.
F2 These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
F3 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date.
F5 Upon exercise, the stock appreciation right will be settled in cash.

Remarks:

President and Chief Operating Officer